Experienced in Primary Amyloidosis

Dr. Edward Y. Zamrini

Neurology
729 Arapeen Dr, Camt Building, Research Park, 
Salt Lake City, UT 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Experienced in Primary Amyloidosis
729 Arapeen Dr, Camt Building, Research Park, 
Salt Lake City, UT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Edward Zamrini is a Neurologist in Salt Lake City, Utah. Dr. Zamrini is rated as an Experienced provider by MediFind in the treatment of Primary Amyloidosis. His top areas of expertise are Dementia, Alzheimer's Disease, Cerebral Amyloid Angiopathy, and Parkinson's Disease. Dr. Zamrini is currently accepting new patients.

His clinical research consists of co-authoring 40 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Primary Amyloidosis.

Specialties
Neurology
Licenses
Psychiatry & Neurology in UT
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Independent Health
  • EPO
  • POS
  • PPO

Locations

729 Arapeen Dr, Camt Building, Research Park, Salt Lake City, UT 84108

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
Enrollment Status: Recruiting
Publish Date: November 21, 2024
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Enrollment Status: Completed
Publish Date: December 28, 2023
Intervention Type: Drug
Study Drug: Solanezumab
Study Phase: Phase 3
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: BIIB092
Study Phase: Phase 2
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: October 13, 2022
Intervention Type: Drug
Study Drug: LY3002813
Study Phase: Phase 2
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
An Open Label, Multicenter Study Evaluating the Imaging Characteristics of a Follow up 18F-AV-1451 Scan in Subjects That Participated in the Confirmatory Cohort of 18F-AV-1451-A05
An Open Label, Multicenter Study Evaluating the Imaging Characteristics of a Follow up 18F-AV-1451 Scan in Subjects That Participated in the Confirmatory Cohort of 18F-AV-1451-A05
Enrollment Status: Completed
Publish Date: August 24, 2020
Intervention Type: Drug, Procedure
Study Phase: Phase 2
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: October 10, 2019
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label Study to Evaluate the Safety and Efficacy of Transcranial Electromagnetic Treatment (TEMT) for the Treatment of Alzheimer's Disease
An Open-Label Study to Evaluate the Safety and Efficacy of Transcranial Electromagnetic Treatment (TEMT) for the Treatment of Alzheimer's Disease
Enrollment Status: Completed
Publish Date: April 23, 2019
Intervention Type: Device
Study Phase: Not Applicable
View 9 Less Clinical Trials

40 Total Publications

Trajectories of Cardiorespiratory Fitness Measured by Metabolic Equivalents and the Risk of Alzheimer's and Related Dementias.
Trajectories of Cardiorespiratory Fitness Measured by Metabolic Equivalents and the Risk of Alzheimer's and Related Dementias.
Journal: The journal of prevention of Alzheimer's disease
Published: February 11, 2025
Similar Doctors
Experienced in Primary Amyloidosis
Dr. Kelsey R. Barrell
Neurology
Experienced in Primary Amyloidosis
Dr. Kelsey R. Barrell
Neurology

University Of Utah Adult Services

50 N Medical Dr, 
Salt Lake City, UT 
 (1.4 miles away)
801-581-7719
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kelsey Barrell is a Neurologist in Salt Lake City, Utah. Dr. Barrell is rated as an Advanced provider by MediFind in the treatment of Primary Amyloidosis. Her top areas of expertise are Peripheral Neuropathy, Hereditary Sensory and Autonomic Neuropathy Type 2, Infantile Axonal Neuropathy, and Congenital Insensitivity to Pain with Anhidrosis. Dr. Barrell is currently accepting new patients.

Experienced in Primary Amyloidosis
Dr. Jennifer J. Majersik
Neurology
Experienced in Primary Amyloidosis
Dr. Jennifer J. Majersik
Neurology

Clinical Neurosciences Center

175 N Medical Dr East, 5th FL Dept Of Neurology, 
Salt Lake City, UT 
 (3.5 miles away)
801-585-7575
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jennifer Majersik is a Neurologist in Salt Lake City, Utah. Dr. Majersik is rated as a Distinguished provider by MediFind in the treatment of Primary Amyloidosis. Her top areas of expertise are Stroke, Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy, Vascular Dementia, Thrombectomy, and Transmyocardial Revascularization. Dr. Majersik is currently accepting new patients.

Experienced in Primary Amyloidosis
Dr. Mark B. Bromberg
Neurology
Experienced in Primary Amyloidosis
Dr. Mark B. Bromberg
Neurology

University Of Utah Adult Services

50 N Medical Dr, 
Salt Lake City, UT 
 (1.4 miles away)
801-585-3229
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Bromberg is a Neurologist in Salt Lake City, Utah. Dr. Bromberg is rated as an Elite provider by MediFind in the treatment of Primary Amyloidosis. His top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Spinal Muscular Atrophy (SMA), Gastrostomy, and Thymectomy. Dr. Bromberg is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Zamrini's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile